A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.

被引：14

作者：

Goldman, Jonathan Wade

Mazieres, Julien

Barlesi, Fabrice

Koczywas, Marianna

Dragnev, Konstantin H.

Goksel, Tuncay

Cortot, Alexis B.

Girard, Nicolas

Wesseler, Claas

Bischoff, Helge

Nadal, Ernest

Park, Keunchil

Lu, Shun

Taus, Alvaro

Cobo, Manuel

Hurt, Karla

Chiang, Alan

Hossain, Anwar

John, William J.

Paz-Ares, Luis G.

机构：

[1] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[2] Ctr Hosp Univ Toulouse, Hop Larrey, Toulouse, France

[3] Hosp Nord Serv Oncol, Marseille, France

[4] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[5] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[6] Ege Univ, Sch Med, Izmir, Turkey

[7] Ctr Hosp Reg Univ Lille, Lille, France

[8] Louis Pradel Hosp Civils Lyon, Lyon, France

[9] Asklepios Klin Harburg, Hamburg, Germany

[10] Thoraxklin, Heidelberg, Germany

[11] Catalan Inst Oncol, Dept Med Oncol, Lhospitalet De Llobregat, Barcelona, Spain

[12] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[13] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

[14] Hosp del Mar, Med Oncol Dept, Barcelona, Spain

[15] Hosp Reg Univ Malaga, Malaga, Spain

[16] Eli Lilly & Co, Indianapolis, IN 46285 USA

[17] Univ Hosp 12 de October, Madrid, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9025

引用

页数：1